The NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) drugs in development market research report provides comprehensive information on the therapeutics under development for NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) and features dormant and discontinued products.

GlobalData tracks six drugs in development for NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) by six companies/universities/institutes. The top development phase for NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) is phase i with two drugs in that stage. The NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) pipeline products market are: Boehringer Ingelheim International, Bristol-Myers Squibb and Zenith Epigenetics.

The key targets in the NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) pipeline products market include Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4), Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT), and Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3).

The key mechanisms of action in the NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) pipeline product include Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Inhibitor with three drugs in Phase I. The NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) pipeline products include one routes of administration with the top ROA being Oral and one key molecule types in the NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) pipeline products market including Small Molecule.

NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) overview

Nuclear protein in testis (NUT) midline carcinoma (NMC) is a rare and aggressive cancer that can grow anywhere in the body. It is caused by rearrangement of the NUTM1 gene. Symptoms include fatigue, weight loss, a painless lump, pain, persistent cough, and shortness of breath. NMC is difficult to diagnose and treat. There is no standard treatment for it because it is so rare. NMC patients are treated with multimodal therapy including surgery, radiation therapy, and chemotherapy.

For a complete picture of NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.